Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Subcutaneous Depot Leuprorelin

Subcutaneous Depot Leuprorelin Am J Cancer 2004; 3 (3): 203 GUEST COMMENTARIES 1175-6357/04/0003-0203/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. patented polymer/solvent system developed by Atrix Laboratories. This formulation can be administered subcutaneously with reliable A Viewpoint by Navjeet Gandhok and Oliver Sartor effects. Department of Hematology/Oncology, Louisiana State University School of Medicine, New Orleans, Louisiana, USA Three multicenter studies with depot leuprorelin in prostate cancer patients have demonstrated consistent testosterone re- sponse to below castration levels by day 21–28 after an initial brief Androgen suppression via luteinizing hormone-releasing hor- increase. The initial increase is due to the agonist qualities of mone (LHRH) analogs is a core treatment modality in advanced leuprorelin and is inconsequential in most prostate cancer patients. prostate cancer, sparing the patient the psychological effects of As expected, serum prostate-specific antigen levels were substan- surgical orchiectomy and the cardiovascular effects of estrogens tially reduced by the drug in patients with prostate cancer, and while providing effective disease palliation. LHRH agonists act by normalized in nearly 95% of the patients at 6–8 months. The most down-regulating pituitary receptor binding sites, thereby decreas- frequent adverse effect was hot flashes (rated subjectively as mild ing luteinizing hormone secretion and reducing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Subcutaneous Depot Leuprorelin

Subcutaneous Depot Leuprorelin

Abstract

Am J Cancer 2004; 3 (3): 203 GUEST COMMENTARIES 1175-6357/04/0003-0203/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. patented polymer/solvent system developed by Atrix Laboratories. This formulation can be administered subcutaneously with reliable A Viewpoint by Navjeet Gandhok and Oliver Sartor effects. Department of Hematology/Oncology, Louisiana State University School of Medicine, New Orleans, Louisiana, USA Three multicenter studies with depot leuprorelin in...
Loading next page...
 
/lp/springer-journals/subcutaneous-depot-leuprorelin-toLCO0uXCz
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403030-00009
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2004; 3 (3): 203 GUEST COMMENTARIES 1175-6357/04/0003-0203/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. patented polymer/solvent system developed by Atrix Laboratories. This formulation can be administered subcutaneously with reliable A Viewpoint by Navjeet Gandhok and Oliver Sartor effects. Department of Hematology/Oncology, Louisiana State University School of Medicine, New Orleans, Louisiana, USA Three multicenter studies with depot leuprorelin in prostate cancer patients have demonstrated consistent testosterone re- sponse to below castration levels by day 21–28 after an initial brief Androgen suppression via luteinizing hormone-releasing hor- increase. The initial increase is due to the agonist qualities of mone (LHRH) analogs is a core treatment modality in advanced leuprorelin and is inconsequential in most prostate cancer patients. prostate cancer, sparing the patient the psychological effects of As expected, serum prostate-specific antigen levels were substan- surgical orchiectomy and the cardiovascular effects of estrogens tially reduced by the drug in patients with prostate cancer, and while providing effective disease palliation. LHRH agonists act by normalized in nearly 95% of the patients at 6–8 months. The most down-regulating pituitary receptor binding sites, thereby decreas- frequent adverse effect was hot flashes (rated subjectively as mild ing luteinizing hormone secretion and reducing

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.